The Value of Intelligent Early Safety Pharmacology Intervention. Derek Leishman PhD Senior Fellow, Global Head of Safety Pharmacology
|
|
- Tiffany Bradley
- 6 years ago
- Views:
Transcription
1 The Value of Intelligent Early Safety Pharmacology Intervention Senior Fellow, Global Head of Safety Pharmacology
2 Outline Part 1: Why do we front-load safety assessment? Part 2: Where does attrition come from? Part 3: Early testing strategy Part 4: Some proposals Conclusions 2
3 Disclaimer I don t normally include this slide but. Maybe its time for a provocative proposal or 6 The views expressed in this presentation are my own and do not necessarily reflect those of Eli Lilly, nor do they always reflect current practice at Eli Lilly 3
4 Part 1: Why Do We Front-Load Safety Assessment? Think as you work, for in the final analysis, your worth to your company comes not only in solving problems, but also in anticipating them. Tom Lehrer The wise man avoids evil by anticipating it. Publilius Sirus (Roman author; 1 st C B.C.) "Worry not about the possible troubles of the future; for if they come, you are but anticipating and adding to their weight; and if they do not come, your worry is useless..." Hugh Blair 4
5 Lessons from 60 Years of Pharmaceutical Innovation Bernard Munos, Corporate Strategy Eli Lilly Nature Reviews Drug Discovery Vol. 8, Dec 2009, Exponentially escalating costs of drug development 5 5
6 Biggest Proportion of Costs Lies in Failure Drug discovery and development is a case of trial and error It follows that a large proportion of what is spent on R&D ends up being spent on failed compounds We need to fail more cheaply We need to learn from the trials and especially the errors Hank McKinnell (former CEO of Pfizer) once said we re failing 98% of the time, if we could fail 96% of the time we d double productivity 6
7 Success Rates Getting Better? Sadly success rates continue to decline Success in Phase 3 to Approval is 65% Success from Phase 2 to Phase 3 continues to fall now 22% The ratio of Phase 1 starts to Approval now around 30:1 The ratio of new target project starts to Phase 1 starts remains difficult to determine 7
8 Early Attrition is High but Cheap 8
9 Part 2: Where Does Attrition Come From? 9
10 Attrition Comes from Different Sources Attrition comes in different flavours Its about the compound! Its about the target! Its about the project execution! Managing attrition due to these different flavours suggests different tactics and timing Safety pharmacology concerned with target-based effects, off-target effects and how these should be brought together 10
11 Target Assessments Can Happen Before The Project is Initiated Target assessments can be built from publicly available information 11 More mature targets have more data available Balance of novelty or being first, over following and needing to differentiate Maintaining a perspective on hypothetical risks is very important Need to identify the key experiments around effects you believe are important and/or likely Target assessments can result in attrition of whole project not just compounds Solutions likely involve other functions (e.g. ADME and PK/PD) and not iterations in functional studies
12 On-Target vs. Off-Target It s about the molecule! = an expression of off-target effects herg is the poster child of off-target effects Where do you best address these off-target effects? WHILE YOU RE MAKING MOLECULES! What value is your first herg data if you gather it immediately prior to first-in-human studies? You are characterizing the candidate and working out how to address potential QT issues around fixed properties of the molecule 12
13 Is it Off- or On-Target? What does a series of compounds need to look like to settle the on- vs. off-target question? Poor selectivity doesn t help Testing high exposures doesn t help Highly similar structures don t help Low bioavailability is potentially surmountable Antagonists when developing agonists help, also doing experiments in knockout animals Another company s experience may imply different structure with same effect implicates target 13
14 Bringing it All Together Good Execution Experiments should form a learning map Not a flow chart or filter funnel Don t continually need to repeat the experiment if we ve learned what we need Identify the key questions Doing no safety pharmacology before the GLP studies is low think Screening all compounds across many assays is also low think The catch how do you know what you don t know 14
15 Part 3: Early Testing Strategy 15
16 Predict What? What does your early study need to predict? All the early assessments should be predictive of effects in man? Or The early assessment should be predictive of the next study e.g. the GLP study How predictive are the assays? How does prevalence impact my strategy? Integrative risk assessments are important, how do you do those? 16
17 Babies and Bath Water False positives are the babies and represent lost opportunity cost False negatives are expensive and potentially very damaging Regulators clearly have to have low toleration of false negatives Pharma seeks to minimize the false positives If you have to choose false negatives must be minimized 17
18 Case 1 Early assessment assay is 80% sensitive and 80% specific for effects in man 20% false positives, 20% false negatives GLP study is similar 80% sensitivity and specificity They re different and the false +ve, false ve don t overlap Can be advantageous in combination a minimum number of positives will make it to man Disadvantage positive in GLP study following months of compound optimization 18
19 GLP Study Early Study True Incidence Scenario 1 Positive TP FP Negative FN TN total Positive 8 18 Negative 2 72 total Positive 2 14 Negative total 2 72 High lost opportunity cost come with high reload costs Effectively excluded false negatives All these examples based on first promising compound in each of the 100 projects being tested. Response to a positive will be make and test a new molecule. Eventually 90 projects may succeed but will take iterations. Can assume time spent in lead optimization for a project team is expensive $1M/month. 19
20 Case 2 Early assessment and GLP study are 80% sensitive and 80% specific for effects in man They re very similar and the false +ve, false ve overlap entirely Can be advantageous no reload cost with unexpected positive Easier to create the predictivity database when comparing two short term animal studies Disadvantage Haven t closed the false negative gap 20
21 GLP Study Early Study True Incidence Scenario 2 Positive TP FP Negative FN TN total Positive 8 18 Negative 2 72 total Positive 0 0 Negative total 2 72 Lost opportunity cost modest and taken early 18 candidates Risk false negatives Rely on early clinical studies to capture false negative These false negative projects are an expensive reload cost depending on where true effect can be observed Could attempt to increase predictivity of both assays 21
22 FIH Study In Vivo Dog herg Real QT Scenario? TQT +ve TQT -ve total Positive Negative 5 53 total TQT +ve TQT -ve total Positive 4 7 Negative 1 46 Total TQT +ve TQT -ve total Positive 1 0 Negative total 1 46 herg effect common but relatively predictable Estimate likelihood of positive TQT was at one time as high as 30% Sensitivity and specificity of assays as described in Wallis, 2010 Nonclinical false negative FIH study believed 100% predictive of TQT Matches current experience with very few +ve TQT studies now 22
23 GLP Study Early Study 2 Early Study 1 Improved Combination Scenario Positive 8 18 Negative 2 72 total Positive 2 14 Negative 0 58 total Positive 0 0 Negative total 0 58 Do two different early assays 2 nd study equivalent to GLP study Lost opportunity cost still relatively high Minimize reload cost as conducted early No false negatives Still largely testing negatives which you d prefer to predict The first assay example here could be in silico or in cerebro 23
24 GLP Study Early Study 2 Early Study 1 Predict The Trouble Compounds Scenario Positive 8 8 Negative 2 32 total Positive 2 6 Negative 0 26 total Positive 0 0 Negative total 0 76 Confidently decide 50 of the 100 molecules unlikely to be positive and exclude from testing Do the two different early assays Lost opportunity cost is now minimized Minimize reload cost Still no false negatives This is effectively the scenario you have when half the portfolio is large molecules 24
25 Focused Early Testing Delivers Number of Candidate Compounds with the Problem Number of Candidate Compounds without the Problem Number of Projects Reaching Man (negative in assays) Best Case Scenario 1 (different predictivity for man) Scenario 2 (same predictivity for man) Scenario 3 (different predictivity for man applied early) No false negatives 14 false positive projects delayed >6 months false negatives (+14, +18?) No false negatives 14 false positive projects minimally delayed Scenario 4 (Focused Testing) (+6, +8?) No false negatives and 7 projects minimally delayed 25
26 GLP Study Early Study 2 Early Study 1 Scenario Tricky Finding #1 Positive 1 49 Negative 1 49 total Positive 1 9 Negative 0 40 total Positive 0 0 Negative total 0 40 Rare event present in 2 out of 100 candidates First assay not at all predictive; 50% sensitivity and 50% specificity Second study remains 80% specific and sensitive Third (GLP) study very similar to 2 nd study High lost opportunity cost 1 st Study must be very early and cheap if want to avoid losing projects 26
27 GLP Study Early Study 2 Early Study 1 Combination Scenario Tricky Finding #2 Positive Negative 5 45 total Positive 4 9 Negative 1 36 total Positive 0 0 Negative total 1 36 Common event present in 25 out of 100 candidates First assay 80% sensitivity and 60% specificty Second study remains 80% specific and sensitive Third (GLP) study very similar to 2 nd study High lost opportunity cost False negative 27
28 GLP Study Early Study 2 Early Study 1 Combination Scenario Tricky Finding #2b Swap Order of Assays Positive Negative 5 60 total Positive 4 24 Negative 1 36 total Positive 0 0 Negative total 1 36 Common event present in 25 out of 100 candidates First assay 80% sensitivity and 80% specificty Second study remains 80% sensitive but 60% specific Effectively reversing the order of the first two studies Third (GLP) study very similar to 2 nd study Same ultimate outcome but tested 15 more compounds in 2 assays 28
29 GLP Study Early Study 2 Early Study 1 Combination Scenario Tricky Finding #2c, Eliminate False -Ve Positive Negative 1 45 total Positive 1 9 Negative 0 36 total Positive 0 0 Negative 0 36 total Common event present in 25 out of 100 candidates Increase first assay to 95% sensitivity and 60% specificty Second study remains 80% specific and sensitive Third (GLP) study very similar to 2 nd study High lost opportunity cost Eliminates the false negative 29
30 Multiple Effects Now imagine 2% incidence of CNS effects 10% incidence of haemodynamic effects 25% incidence of QTc effects Liver effect, PK suboptimal Different predictivity in the now multiple early assays Some assays 85% sensitive, 85% specific Some assays less predictive Do the math It takes a lot of resource It takes much longer than you d like 30
31 Learning? Speed and efficiency are best served with early and GLP studies which predict each other very well, but risk missing something Combinations of assays with different spectrums of predictivity can minimize late surprises Must both be applied early to add to speed and efficiency Effectively identifying problem series then applying two tests would be very effective Need to match assay to prevalence where effects are rare raise specificity, where effects common increase sensitivity Lost opportunity through false positives are inevitable minimize reload cost 31
32 Screening vs Focused Evaluation Early studies are attractive to tackle attrition but how many do you want to pay for? More effective when exclude testing predicted negatives This reduces cost If it takes more than 50 lead optimization projects to produce a drug how many compounds need to be made? How many do you test and in how many screening studies? 250 compounds? 5 assays? Worst case 1250 studies Even at $1000 each = $1.25M They may be cheap but be careful of volume 32
33 So Why Screen? How do you know where to focus your efforts? Prevalent effects (limited proportion of negative assays make screening more cost effective) If you have to screen Make it cheap Consider sentinel philosophy Build in silico models may mean generating IC 50 rather than single concentration In silico models ultimately save even more since you don t make as many positive compounds 33
34 <1 >1 & <3 >3 & <10 >10 & <30 >30 & <100 >100 & <300 >300 & <1000 >1000 & <3000 >3000 & <10000 >10000 & <30000 >30000 & < > Percentage of Compounds How Common Is herg Block? % of Compounds (n=1686) % of Compounds 5 0 [3H] Dofetilide Binding herg IC50 (nm) 34
35 SHARING IN EACH OTHER S FAILURES TO HELP US ALL BE SUCCESSFUL 35
36 Proposal 1 Facilitate Target-Safety Assessment Create a database of target-related safety e.g. Wiki Start with key systems and relatively common targets Use an independent group to host the database e.g. SPS Grows from pilot exercise (Gul Erdmeli, Steve Jenkinson) Partner with academia? 36
37 Proposal 2 Share Early Assay Experience Share in silico models with smaller companies who don t have the depth of experimental experience to build the models Retain no structural information Use an independent group to host the models e.g. SPS Have additional tutorial information to follow if in silico models suggest potential effects Fund in itunes-like manner, small cost per structure tested 37
38 Proposal 3 Facilitate Understanding of Predictivity 1. Share translation information to facilitate assessment of the predictivity of nonclinical studies Increased numbers increases confidence in predictivity 2. Use an independent group to host the sharing Already good examples e.g. ILSI-HESI QT and CV, ABPI & AMF, TI Pharma Current examples are static no facility to constantly add new information and thus assess impact of new methods and technology 5. Maximize funds by avoiding duplication and by ensuring complimentary efforts 38
39 Proposal 4 Share Regulatory Studies Facilitate understanding of on- vs. off-target Example in your GLP studies you observe an effect. You know another company has also been developing compounds against this target. They have also conducted a GLP study. Question: did they see the same thing? Share outcomes of GLP studies in a manner similar to clinicaltrials.gov 39
40 Proposal 5 Increase Quality and Consistency Cross company consistency for the same assays becomes very important Need to understand that similar studies have similar sensitivity and quality Best Practice Need to make quality data affordable for all Need an incentive to quality needn t be a regulator, cross pharma group such as IQ & SPS consortium? 40
41 Proposal 6 Focus vs. Blinkered Stop worrying about ICH S7 Guideline has some elements pointing to long term patient toleration, it is however primarily intended to facilitate FIH Safety pharmacology effects can be important whether or not they are in core studies Increase sharing in non ICH S7- related information ICH S7 41
42 Conclusions We need to make what we do now efficient so we have the resources for the new challenges Early assessment is the direction to take but it needs to be focused to minimize resource burn Sharing knowledge and data are critical to our overall success A treasure trove of proprietary information may be useless if the ship sinks SHARE! 42
Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationThe Envision process Defining tomorrow, today
The Envision process Defining tomorrow, today Because life and the markets change over time, you need an investment plan that helps you know exactly where you stand now, tomorrow, and in the years to come.
More informationFebruary 28, Churchill Place Canary Wharf London E14 5EU United Kingdom
February 28, 2017 Submission of comments on 'Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products' (EMEA/CHMP/SWP/28367/07
More informationInsights On Video Interviewing
Insights On Video Interviewing Written by David Creelman Sponsored by videointerview_whitepaper_hirevue_060616.indd Introduction There s no doubt that video interviewing is fascinating, but is it a technology
More informationDesigning Safe and Efficient Phase I Studies to Expedite Clinical Development
Designing Safe and Efficient Phase I Studies to Expedite Clinical Development Mario Tanguay, B.Pharm, Ph.D. Vice President, Scientific & Regulatory Affairs, Anapharm Guest Professor, Faculty of Pharmacy,
More informationPharma EXPO 6 9 November 2016 Chicago, IL
DESIGN TO VALUE: An End-to-end Lifecycle Methodology, Enabling Customer-centric, High-quality Products, Made Efficiently and Reliably Susan Neadle Senior Director Design to Value & Product Quality Management
More informationCelerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014
Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept San Francisco, CA Tue 8 th, Apr 2014 Mind the Gap: Elements of a Bridging Strategy J. Fred Pritchard, Ph.D. Vice President,
More informationEffective Pricing Using Profitability Insight: A Best Practice Guide
White Paper Effective Pricing Using Profitability Insight: A Best Practice Guide Torsten Weirich Chief Technical Officer, Acorn Systems March 2009 2009 Acorn Systems Introduction The benefits of an effective
More informationGlobal Development Challenges: Classical and Advanced Therapy Medicinal products
Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES
More informationDefining the CiPA Paradigm: An Update from the Ion Channel Working Group (ICWG) Bernard Fermini Pfizer Inc. Global Safety Pharmacology For the ICWG
Defining the CiPA Paradigm: An Update from the Ion Channel Working Group (ICWG) Bernard Fermini Pfizer Inc. Global Safety Pharmacology For the ICWG Ion Channel Working Group (ICWG) CiPA initiative is a
More informationTuberculosis Drug Accelerator
Tuberculosis Drug Accelerator Overview of Activities and Portfolio who, why, what, how, by when and where are we now Steve Berthel 1 What is the Tuberculosis Drug Accelerator? The A is a groundbreaking
More information7 TIPS TO SUPER-CHARGE CORNERSTONE
7 TIPS TO SUPER-CHARGE CORNERSTONE You have great talent. You have a great platform. How can you go even further? GOALS DEVELOPMENT PLANNING TRAINING CREATIVITY VISION LEARNING www.tribridge.com/hcm hcm@tribridge.com
More informationBIOPHARMA SOLUTIONS TM Expedite Your Drug Development Program
BIOPHARMA SOLUTIONS TM Expedite Your Drug Program Maximize the Value of Your Asset The journey of drug development can be complex stressful. But it doesn t have to be that way. Join more than 600 biopharmaceutical
More informationSUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007
European Medicines Agency SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007 COMMENTS FROM The Biotechnology
More informationAN UNCOMMON SENSE OF THE CONSUMER. Nurturing Innovation: HOW TO SUCCEED IN YEARS TWO AND THREE
AN UNCOMMON SENSE OF THE CONSUMER Nurturing Innovation: HOW TO SUCCEED IN YEARS TWO AND THREE NIELSEN INNOVATION BEST PRACTICES REPORT SERIES JUNE 2015 INTRODUCTION At Nielsen, we already know that failure
More informationCosmetics Europe LRSS Programme
Cosmetics Europe LRSS Programme 2016-20 Rob Taalman Objectives of CE Research To deliver tools & strategies for animal-free safety assessment Accurate Robust Efficient ultimately accepted by regulators
More informationXpertHR Podcast. Original XpertHR podcast: 22 September 2017
XpertHR Podcast Original XpertHR podcast: 22 September 2017 Hi and welcome to this week s XpertHR podcast with me, Ellie Gelder. Now TUPE, possibly not a term that inspires enthusiasm amongst a lot of
More informationOptimisation de votre programme de développement
Optimisation de votre programme de développement Cedric Lamy, PhD. Cedric.lamy@crl.com Charles River Overview 65-year history: Founded in 1946, publicly traded (NYSE:CRL) Investment in skilled staff: ~7,500
More informationScope Creep: need strong change control to prevent or mitigate. Must establish the change control system early in the project.
Scope Creep: need strong change control to prevent or mitigate. Must establish the change control system early in the project. HBS Article: value of scope creep; delays & overruns vs market opportunities.
More informationEmerging Trends in Regulatory Outsourcing WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting You are not alone in the quest for bringing your products to market and improve the quality of the life for millions! MakroCare brings you the insight on how a
More informationEnabling faster insights to improve clinical trial efficiency and quality
Enabling faster insights to improve clinical trial efficiency and quality Clarity, understanding and confidence Every clinical trial has moments when decisive action is needed to set the course for a
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationThe Project Confidence Book. Eight best practices for driving project confidence
The Project Confidence Book Eight best practices for driving project confidence With $57 trillion in spend expected by 2030, the capital project industries remain challenged to deliver projects on time
More informationPROTECT & UNLOCK YOUR VALUE THROUGH SUCCESSION PLANNING
PROTECT & UNLOCK YOUR VALUE THROUGH SUCCESSION PLANNING INSIDE How succession planning can help increase your practice value Avoiding the top transition pitfalls Timing your exit to maximize value Simplified
More informationFoundations for an Effective Quality Relationship with Contract Manufacturers
Foundations for an Effective Quality Relationship with Contract Manufacturers Fionnuala Walsh Senior Vice President Global Quality Eli Lilly and Company PQRI/FDA Conference September 2014 Eli Lilly and
More informationAddressing attrition in neurosciences. Dr Ismail Kola Head UCB NewMedicines
Addressing attrition in neurosciences Dr Ismail Kola Head UCB NewMedicines Disclaimer and safe harbour Forward-looking statements: This presentation contains forward-looking statements based on current
More informationMaximizing the value from technology investments Spending smart instead of just spending big
Maximizing the value from technology investments Spending smart instead of just spending big Contacts Chicago Michael Cooke Principal, PwC US +1-312-578-4639 mike.cooke @strategyand.us.pwc.com Los Angeles
More informationClinical Trial Simulations
Clinical Trial Simulations Clinical Pharmacology meeting 07.10. 2014 Flora T Musuamba Outline Introduction Estimation vs Simulations Simulations as a diagnostic tool Simulation as a tool for quantitative
More informationThe use of integrated in silico solutions under the proposed ICH M7 guidelines
The use of integrated in silico solutions under the proposed ICH M7 guidelines SOT Phoenix, March 2014 Dr Chris Barber Director of Science chris.barber@lhasalimited.org The use of integrated in silico
More informationScienceDirect. Survey Framework for Understanding Value of Service
1 ScienceDirect Survey Framework for Understanding Value of Service 2 How we strive to help you This guide strives to provide our customers with framework to help identify the organizational value of having
More informationApril 13, Background
Pfizer Inc 235 East 42nd Street New York, NY 10017-5755 Tel 212 733 4210 Fax 646 383 9249 Email: marc.wilenzick@pfizer.com April 13, 2009 http://www.regulations.gov Christine Ireland Committee management
More informationBest Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Specifications Breakout Session 2 Pete Yehl and Mike Coutant, moderators
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationDevOps Guide: How to Use APM to Enhance Performance Testing
DevOps Guide: How to Use APM to Enhance Performance Testing CHAPTER 1: Introduction This short ebook discusses how combining performance test automation with application performance management (APM) solutions
More informationGoing Big Data? You Need A Cloud Strategy
A Forrester Consulting January 2017 Thought Leadership Paper Commissioned By Oracle And Intel Going Big Data? You Need A Cloud Strategy Table Of Contents Executive Summary... 1 Big Data Investment Shifts
More informationIndustry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development
Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development Aernout van Haarst PhD Director, European Corporate Development Feb 2016 Industry Academic Collaboration
More informationSiebel CRM On Demand Administrator Rollout Guide
Siebel CRM On Demand Administrator Rollout Guide This Administrator Rollout Guide consolidates tips and lessons learned from implementing Siebel CRM On Demand, discusses your role as an administrator,
More informationStrategic Intelligence for Law Firms
Strategic Intelligence for Law Firms EDITED BY LAURA SLATER Strategic-Intelligence_RO_2016.indd i 25/08/2016 13:49 Chapter 1: Client success through better intelligence By Mark Medice and Jennifer Roberts
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS
More informationOwning An Agile Project: PO Training Day 2
Owning An Agile Project: PO Training Day 2 Petri Heiramo Agile Coach, CST Product Management PO Product management is a larger scope than what Scrum defines as a PO Or rather, Scrum implicitly assumes
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
More informationAgile TesTing MeTrics Quality Before Velocity
Agile TesTing MeTrics Quality Before Velocity Some people never weigh themselves. They may say, i just look at my clothes. if they don t fit, then i know i should lose weight. On the other hand, some people
More informationThe Right Molecules. Designed. Delivered.
The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered
More informationgetting the most out of the middle thought paper
thought paper getting the most out of the middle Why your middle and frontline managers are more important than ever - and how to make sure they succeed 03 introduction 04 what's changed and why 05 a shift
More informationStatisticians in the Pharmaceutical Industry: The 21 st Century
Statisticians in the Pharmaceutical Industry: The 21 st Century Christy Chuang-Stein, Pfizer Ray Bain, Merck Cassie Burton, Novartis Cyrus Hoseyni, Wyeth Frank Rockhold, GlaxoSmithKline Stephen Ruberg,
More informationCFO #CFOPERFORMANCE. Understanding and Managing Risk In Professional Service Firms
#CFOPERFORMANCE Understanding and Managing Risk In Professional Service Firms Your firm didn t get where it is now by ignoring risks. Today, as professional service firms look for opportunities to expand
More informationNon-clinical documentation Overview of Requirements
3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements
More informationSPEED UP YOUR TIME TO MARKET
SPEED UP YOUR TIME TO MARKET #Pre-clinical #Biologics #Small molecules Welcome to Accelera. As a Contract Research Organization (CRO) serving since more than 30 years pharmaceutical and biotechnology companies
More informationParadigm Shift in Comparability Assessment:
Paradigm Shift in Comparability Assessment: How Quality by Design (QbD) and Process Analytical Technology (PAT) can improve Structure-Activity Relationship (SAR) evaluation and its relevance to comparability
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationEarly Phase Education WHITEPAPER. Three major items to consider when moving from preclinical to clinical development
Early Phase Education WHITEPAPER Three major items to consider when moving from preclinical to clinical development Three major items to consider when moving from preclinical to clinical development Dr.
More informationCreating Outsourcing Success:
Creating Outsourcing Success: Avoid the Pitfalls and Gain Competitive Advantage Through High Impact Customer Communications Outsourcing customer communications can be an effective way to bring world-class
More informationEU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective
EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development
More informationA gateway to academic excellence for Biotech and Pharma
A gateway to academic excellence for Biotech and Pharma 6 8 12 Connecting meaningful endpoints: Ksilink s comprehensive translational effort Ksilink s patient centered, translational technology Engaging
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More informationManagement in Pharmaceutical Industry
Master Program Management: Industrial Management Module: Chemistry for Drug Substances Management in Pharmaceutical Industry Prof. Tatsiana Savitskaya Assoc. Prof. Iryna Kimlenka Lectures 5,6 The Key Aspects:
More informationRechanneling the Cardiac Proarrhythmia Safety Paradigm: An Update
Rechanneling the Cardiac Proarrhythmia Safety Paradigm: An Update Synopsis of the December 11 th, 2014 FDA/CSRC/HESI/SPS Think Tank Meeting Introduction and Background The year 2015 marks the 10 th anniversary
More informationTHE HR GUIDE TO IDENTIFYING HIGH-POTENTIALS
THE HR GUIDE TO IDENTIFYING HIGH-POTENTIALS What makes a high-potential? Quite possibly not what you think. The HR Guide to Identifying High-Potentials 1 If you agree people are your most valuable asset
More informationENTERPRISERISK WHY YOU NEED RISK COMMITTEE. 18 April 2014 The RMA Journal Copyright 2014 by RMA
ENTERPRISERISK WHY YOU NEED A RISK COMMITTEE 18 April 2014 The RMA Journal Copyright 2014 by RMA With schedules already crammed with committee meetings, it s tempting to reject the idea of forming yet
More informationThe Aptuit Center for Drug Discovery & Development Verona, Italy
The Aptuit Center for Drug Discovery & Development Verona, Italy 2 The Aptuit Center for Drug Discovery & Development Verona, Italy Aptuit in Verona: uncommon expertise, exceptional results A knowledgeable
More informationWe've all heard the dismal statistics: 10,000 known diseases with only 500 treatments. Not great odds if you're a patient.
No longer just passengers, patients are now co-pilots helping to navigate the future of medical progress. But until recently, the pace of progress has been slow. In some diseases, we still utter the words
More informationManaging Your Backlog
Managing Your Backlog A brief guide for Scrum Product Owners by Richard Lawrence Last updated 5/12/2014 Managing Your Backlog by Richard Lawrence 1 The Challenge of the Product Owner Role For years, I
More informationREWARD & RECOGNITION REPORT
REWARD & RECOGNITION REPORT AUSTRALIA & NZ 2012 Key trends & insights to drive your people & business forward. An introduction This latest survey conducted by RedBalloon for Corporate was undertaken to
More informationThe Game of Life Predictable Life Crises Updated:
The Game of Life Predictable Life Crises Updated: 2016-02-10 There are a number of life crises that are common in the lives of young people at the beginning of their careers. These life crises are: 1)
More informationA full-service CRO with integrated early-stage capabilities
CHARLES RIVER TO ACQUIRE ARGENTA and BIOFOCUS A full-service CRO with integrated early-stage capabilities James C. Foster Chairman, President & CEO Thomas F. Ackerman Executive Vice President & CFO March
More informationRisk-Based Approach to SAS Program Validation
Paper FC04 Risk-Based Approach to SAS Program Validation Keith C. Benze SEC Associates, Inc. 3900 Paramount Parkway, Suite 150 South Morrisville, NC 27560 ABSTRACT SAS is widely used throughout the FDA
More informationEuropean Induced Pluripotent Stem Cell Bank
European Induced Pluripotent Stem Cell Bank Background Researchers are looking for ways to validate pathways using human data. ips cells are one approach to this. ips research and banking is fragmented
More informationPharmaceutical Reviews Year: 2008 Vol: 6 Issue: 1 ISSN: School of Pharmacy and Technology Management, NMiMS University, Mumbai
Dayanidhi B, Amol S School of Pharmacy and Technology Management, NMiMS University, Mumbai The US$65-billion (in 2005), global R&D pie is expected to grow to US$l00-billion by 2010. If India secures even
More informationB2B Sales in the Modern Age
B2B Sales in the Modern Age Using Insight Selling to Improve Sales and Marketing Results When it comes to lead generation and improving customer relationships, it seems that sales and marketing professionals
More informationTraining where is the dividend?
In this article we pose the question Why, after so much training, are organisations still struggling with programme and project performance, where is the dividend? Organisations have spent a fortune on
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationVisions on the role of Statisticians in the Pharmaceutical Industry. Merete Jørgensen President EFSPI VP Biostatistics, Novo Nordisk A/S
Visions on the role of Statisticians in the Pharmaceutical Industry Merete Jørgensen President EFSPI VP Biostatistics, Novo Nordisk A/S Overview of presentation Vision & Mission A Historical view New Statistical
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationRisk Management: FDA and Industry Experience. Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc.
Risk Management: FDA and Industry Experience Dan Snider, Ph.D Vice President Morgantown RD Mylan Pharmaceuticals Inc. Disclaimer This presentation contains a summary of the opinion and perspective from
More informationBehavior-Based Safety Programs. Christina Kulakowski May 15, 2017
Behavior-Based Safety Programs Christina Kulakowski May 15, 2017 Risk Risk is inherent in everything we do. Risk never goes away. How do we get employees to make decisions and behave in ways to reduce
More informationAdopting Virtual R&D in Drug Development
Adopting Virtual R&D in Drug Development 2016 Table of Contents 1. Why virtual R&D? 2. Project management team for drug development 3. Project initiation 4. Clinical study team considerations for virtual
More informationHow can pharma outsourcing partners overcome the challenges of a rapidly changing industry?
How can pharma outsourcing partners overcome the challenges of a rapidly changing industry? ADAPTING TO CHANGE IN CONTRACT PHARMA How can pharma outsourcing partners overcome the challenges of a rapidly
More informationPassive Immunization Trials to Inform Vaccine Design
Passive Immunization Trials to Inform Vaccine Design Points for Consideration from deliberations held at the August 8, 2014 workshop Contents I. Introduction... 2 II. Types of trials... 2 1. Therapeutic
More informationContinual Reassessment Method for First-in-Human Trial: From Design to Trial Implementation
Continual Reassessment Method for First-in-Human Trial: From Design to Trial Implementation Inna Perevozskaya Statistical Research and Consulting Center, Pfizer in collaboration with Lixin Han, Infinity
More informationAdaptive Design for Medical Device Development
Adaptive Design for Medical Device Development A guide to accelerate clinical development and enhance portfolio value Executive Summary In May 2015, the FDA released a draft guidance document regarding
More informationCritical Quality Attributes for Biotechnology Products: A Regulatory Perspective
Critical Quality Attributes for Biotechnology Products: A Regulatory Perspective Patrick G. Swann, Ph.D. Deputy Director Division of Monoclonal Antibodies Office of Biotechnology Products Office of Pharmaceutical
More informationuniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients
More information* For Smarties. Design of Clinical Drug Development Programs* Objectives 4/19/2012. Disclaimer
Design of Clinical Drug Development Programs* * For Smarties Dr Christopher D Breder 4/12 1 Disclaimer The views expressed in this talk represent my opinions and do not necessarily represent the views
More informationWHEN SCHEDULING IS OUT OF CONTROL
WHEN SCHEDULING IS OUT OF CONTROL Overview When scheduling is out of control, the production schedule is in a constant state of flux and chaos reigns on the shop floor. This is not an uncommon situation
More informationImmunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009
Immunotoxicology Technical Committee (ITC) HESI Assembly of Members January 19, 2009 Committee Leadership Dr. Ellen Evans (Schering-Plough Research Institute), Chair Dr. Tom Kawabata (Pfizer Inc.), Vice
More informationOutline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD
CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables
More informationRegulatory Approaches for New Drugs: BA/BE of Topical Drug Products
Regulatory Approaches for New Drugs: BA/BE of Topical Drug Products CAPT E. Dennis Bashaw, Pharm.D Director, Division of Clinical Pharmacology-3 Office of Clinical Pharmacology Office of Translational
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationExpectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective
Expectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective Christian Mayer AGES - Austrian Agency for Health and Food Safety Analytical Technologies Europe
More informationThe TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices
A leading Australian contract research organisation (CRO) providing integrated preclinical drug development services to the biotech and pharmaceutical industries The TetraQ Difference Located at The University
More informationIN THE ABSENCE OF GOOD DATA ONE CANNOT MAKE GOOD BUSINESS DECISIONS
ONE CANNOT MAKE GOOD BUSINESS DECISIONS Ellen Freedman, CLM Law Practice Management Coordinator Pennsylvania Bar Association Please indulge me for a minute: reread the title of this article. OK, now one
More informationNovartis Business Services HR University Relations. Clinical Sciences and Innovation. Postgraduate Program
Novartis Business Services HR University Relations Clinical Sciences and Innovation Postgraduate Program 2 CLINICAL SCIENCES AND INNOVATION CLINICAL SCIENCES AND INNOVATION 3 The CS&I Postgraduate Program
More informationHow to Become a Demand Planning Rock Star
How to Become a Demand Planning Rock Star For the Chemicals Industry By Jonathan Feinbaum Executive Summary At many companies, demand planners often work as a team of one, gathering data and interpreting
More informationAssurance of Supply. How Confidence in a Reliable Supply Stream Creates Healthy Companies. A GT Nexus White Paper
Assurance of Supply How Confidence in a Reliable Supply Stream Creates Healthy Companies A GT Nexus White Paper One of the greatest supply chain challenges that companies face today is to reliably and
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationStrategic Meetings Management: Solutions and Consolidation Opportunities
About Egencia Meetings & Incentives Egencia Meetings & Incentives combines strategic meetings management expertise with fullservice meeting and incentive planning, all backed by an expert team of meetings
More information8. Fostering Indian Clinical Trials Industry. 8.1 Clinical Trials Opportunity. Strategy for Increasing Exports of Pharmaceutical Products
8. Fostering Indian Clinical Trials Industry 8.1 Clinical Trials Opportunity India has significant valid population to participate in clinical trials and the country also has proven capabilities in medical
More informationData Collection Systems
Data Collection Systems David Embrey PhD Managing Director Human Reliability Associates Ltd 1. An Overview of Data Collection Systems The function of this document is to provide an overall framework within
More information